Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes

References

• Valeria C, Carmine S, Valentina M, et al. The need of a multicomponent guiding approach to personalize clopidogrel treatment. Pharmacogenomics J. 2021;21(2):116–127. doi:10.1038/s41397-020-00189-2
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134(10):e123–155. doi:10.1161/CIR.0000000000000404
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. The Lancet. 2010;376(9749):1312–1319. doi:10.1016/S0140-6736(10)61273-1
   PubMed Web of Science ®Google Scholar
• Kassogue Y, Dehbi H, Nassereddine S, Quachouh M, Nadifi S. Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco. DNA Cell Biol. 2013;32(10):582–588. doi:10.1089/dna.2013.2108
   PubMed Web of Science ®Google Scholar
• Lewis JP, Backman JD, Reny JL, et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J. 2020;6(4):203–210. doi:10.1093/ehjcvp/pvz045
   Web of Science ®Google Scholar
• Polasek TM, Doogue MP, Miners JO. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther Adv Drug Saf. 2011;2(6):253–261. doi:10.1177/2042098611422559
   PubMedGoogle Scholar
• Stokanovic D, Nikolic VN, Konstantinovic SS, et al. P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology. 2016;97(3–4):101–106. doi:10.1159/000442712
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Li MP, Tang J, Chen XP. Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: evidences and Perspectives. Int J Environ Res Public Health. 2017;14(3):301. doi:10.3390/ijerph14030301
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006;319(3):1467–1476. doi:10.1124/jpet.106.110577
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Belmonte C, Caniego JL, et al. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. Clin Ther. 2019;41(6):1199–1212.e2. doi:10.1016/j.clinthera.2019.04.037
   PubMed Web of Science ®Google Scholar
• Singh M, Shah T, Adigopula S, et al. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J. 2012;64(4):341–352. doi:10.1016/j.ihj.2012.06.003
   PubMedGoogle Scholar
• Bellemain-Appaix A, Montalescot G, Silvain J, et al. Slow Response to Clopidogrel Predicts Low Response. J Am Coll Cardiol. 2010;55(8):815–822. doi:10.1016/j.jacc.2009.08.082
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Harmsze AM, Elsenberg EHAM, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets. 2008;19(7):479–488. doi:10.1080/09537100802317918
   PubMed Web of Science ®Google Scholar
• Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res. 2007;119(3):277–284. doi:10.1016/j.thromres.2006.01.019
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223. doi:10.1038/gim.2016.87
   PubMed Web of Science ®Google Scholar
• Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278–281. doi:10.1186/1479-7364-4-4-278
   PubMedGoogle Scholar
• Saiz-Rodríguez M, Ochoa D, Belmonte C, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33(4):522–531. doi:10.1177/0269881119827959
   PubMed Web of Science ®Google Scholar
• Watanabe T, Saito T, Rico EMG, et al. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. Biochem Pharmacol. 2018;156:420–430. doi:10.1016/j.bcp.2018.09.010
   PubMed Web of Science ®Google Scholar
• Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo. Drug Metab Dispos. 2012;40(4):717–725. doi:10.1124/dmd.111.042416
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. J Vasc Surg. 2009;49(4):1083. doi:10.1016/j.jvs.2009.02.023
   Google Scholar
• Sreedharan S, Churilov L, Chan J, et al. Association between CYP2C9 polymorphisms and ischemic stroke following endovascular neurointervention. J Stroke Cerebrovasc Dis. 2020;29(8):104901. doi:10.1016/j.jstrokecerebrovasdis.2020.104901
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–2436. doi:10.1111/j.1538-7836.2007.02775.x
   PubMed Web of Science ®Google Scholar
• Yi X, Lin J, Wang Y, et al. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. J Atheroscler Thromb. 2016;23(10):1188–1200. doi:10.5551/jat.33290
   PubMed Web of Science ®Google Scholar
• Namazi S, Sahebi E, Azarpira N, Rostami-Yalmeh J, Kojuri J, Khalili A. Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous Coronary Intervention. Iran J Pharm Res. 2020;19(2). doi:10.22037/ijpr.2020.1101083
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857. doi:10.1001/jama.2009.1232
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 2009;5(8):989–1004. doi:10.1517/17425250903107772
   PubMed Web of Science ®Google Scholar
• Biswas M, Rahaman S, Biswas TK, Ibrahim B. Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(12):1605–1616. doi:10.1080/14740338.2020.1836152
   PubMed Web of Science ®Google Scholar
• Holmberg MT, Tornio A, Paile‐Hyvärinen M, et al. CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. Clin Pharmacol Ther. 2019;105(2):448–457. doi:10.1002/cpt.1177
   PubMed Web of Science ®Google Scholar
• Ford NF. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. J Clin Pharmacol. 2016;56(12):1474–1483. doi:10.1002/jcph.769
   PubMed Web of Science ®Google Scholar
• Idrissi HH, Hmimech W, Khorb NE, Akoudad H, Habbal R, Nadifi S. Association of the C3435T Multi-Drug Resistance Gene-1 (MDR-1) Polymorphism with Clopidogrel Resistance among Moroccan Acute Coronary Syndromes (ACS) Patients. J Thromb Circ Open Access. 2016;02(4):115. doi:10.4172/2572-9462.1000115
   Google Scholar
• Dong WX, Fu ZD, Bo LX, et al. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Intern Med. 2012;23(1):48–53. doi:10.1016/j.ejim.2011.07.016
   PubMed Web of Science ®Google Scholar